Stocks · News reference
Ascendiant Capital analyst Edward Woo maintains PAVmed (NASDAQ:PAVM) with a Buy and raises the price target from $56 to $57.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Lucid Diagnostics Inc., a majority-owned subsidiary of PAVmed Inc., has begun receiving Medicare reimbursement for its EsoGuard® Esophageal DNA Test and completed a $15 million private placement of Series C Convertible Preferred Stock.
Filed: 2026-10-22 AccNo: 0001493152-26-048138 Size: 207 KB Item 1.01: Entry into a Material Definitive Agreement Item 3.03: Material Modifications to Rights of Security Holders Item 9.01: Financial Statements and Exhibits
Wall Street analysts changed outlook on top names: Evercore raised Salesforce target, Needham raised Nutanix target, Ascendiant raised PAVmed target, Cantor raised Okta target, Piper raised Veeva target, Cantor boosted Solid Biosciences target, BTIG raised Crowdstrike target, Cantor cut Dycom target.